{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:17:14Z","timestamp":1787807834520,"version":"build-2784847793"},"reference-count":176,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020670","name":"Cancer Council Australia","doi-asserted-by":"publisher","award":["MCR2282"],"award-info":[{"award-number":["MCR2282"]}],"id":[{"id":"10.13039\/501100020670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021954","name":"Tour de Cure","doi-asserted-by":"publisher","award":["RSP-712-2026"],"award-info":[{"award-number":["RSP-712-2026"]}],"id":[{"id":"10.13039\/501100021954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000950","name":"Cancer Council South Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jconrel.2026.115166","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:39:46Z","timestamp":1783528786000},"page":"115166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Oral delivery of topoisomerase I inhibitors: From biopharmaceutical barriers to clinical translation"],"prefix":"10.1016","volume":"397","author":[{"given":"Ali","family":"Taheri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen E.","family":"Bremmell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane M.","family":"Hickey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive A.","family":"Prestidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2026.115166_bb0005","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12551-016-0240-8","article-title":"The dynamic interplay between DNA topoisomerases and DNA topology","volume":"8","author":"Seol","year":"2016","journal-title":"Biophys. Rev."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115166_bb0010","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41467-021-27686-7","article-title":"Topoisomerase I (TOP1) dynamics: conformational transition from open to closed states","volume":"13","author":"Takahashi","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0020","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/bjc.2011.498","article-title":"Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets","volume":"106","author":"Gilbert","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115166_bb0025","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.3390\/biom5031652","article-title":"Inhibition of topoisomerase (DNA) I (TOP1): DNA damage repair and anticancer therapy","volume":"5","author":"Xu","year":"2015","journal-title":"Biomolecules"},{"issue":"22","key":"10.1016\/j.jconrel.2026.115166_bb0030","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1158\/1078-0432.CCR-19-1089","article-title":"Targeting topoisomerase I in the era of precision medicine","volume":"25","author":"Thomas","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115166_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114304","article-title":"Topoisomerase I inhibitors: challenges, progress and the road ahead","volume":"236","author":"Talukdar","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115166_bb0040","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/bjc.2014.378","article-title":"Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase","volume":"111","author":"Znojek","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"12","key":"10.1016\/j.jconrel.2026.115166_bb0045","first-page":"2350","article-title":"Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?","volume":"7","author":"Li","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115166_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104398","article-title":"Irinotecan: 25 years of cancer treatment","volume":"148","author":"Bailly","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115166_bb0055","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.hoc.2012.03.002","article-title":"Topoisomerase 1 inhibitors and cancer therapy","volume":"26","author":"Moukharskaya","year":"2012","journal-title":"Hematol.\/Oncol. Clin."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115166_bb0060","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1078-0432.CCR-22-3640","article-title":"New life of topoisomerase I inhibitors as antibody\u2013drug conjugate warheads","volume":"29","author":"Pommier","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"S4","key":"10.1016\/j.jconrel.2026.115166_bb0065","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1634\/theoncologist.6-suppl_4-12","article-title":"Answering patients\u2019 needs: oral alternatives to intravenous therapy","volume":"6","author":"Borner","year":"2001","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.jconrel.2026.115166_bb0070","article-title":"Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer","volume":"28","author":"Ciruelos","year":"2019","journal-title":"Eur. J. Cancer Care (Engl.)"},{"key":"10.1016\/j.jconrel.2026.115166_bb0075","first-page":"1609","article-title":"Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature","author":"Eek","year":"2016","journal-title":"Patient Prefer. Adherence"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0080","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","article-title":"Patient preferences for oral versus intravenous palliative chemotherapy","volume":"15","author":"Liu","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115166_bb0085","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/NAN.0b013e31824237ce","article-title":"Intravenous therapy: a review of complications and economic considerations of peripheral access","volume":"35","author":"Dychter","year":"2012","journal-title":"J. Infus. Nurs."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115166_bb0090","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10198-021-01278-0","article-title":"The cost of chemotherapy administration: a systematic review and meta-analysis","volume":"22","author":"Sohi","year":"2021","journal-title":"Eur. J. Health Econ."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115166_bb0095","doi-asserted-by":"crossref","first-page":"A133","DOI":"10.1016\/j.jval.2013.03.648","article-title":"The costs of oral versus intravenous chemotherapy in insured, low income patients with breast or colon cancer","volume":"16","author":"Noxon","year":"2013","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0100","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1517\/14740338.4.1.45","article-title":"Toxicity of the topoisomerase I inhibitors","volume":"4","author":"Seiter","year":"2005","journal-title":"Expert Opin. Drug Saf."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115166_bb0105","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/BF00686188","article-title":"Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors","volume":"36","author":"Houghton","year":"1995","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0110","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/(SICI)1097-0215(19970926)73:1<156::AID-IJC24>3.0.CO;2-D","article-title":"Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice","volume":"73","author":"Vassal","year":"1997","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0115","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/pbc.22690","article-title":"A phase II study of metronomic oral topotecan for recurrent childhood brain tumors","volume":"56","author":"Minturn","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"issue":"5","key":"10.1016\/j.jconrel.2026.115166_bb0120","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/pbc.22410","article-title":"Oral irinotecan for treatment of pediatric solid tumors: ready for prime time?","volume":"54","author":"Wagner","year":"2010","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.jconrel.2026.115166_bb0125","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/0959-8049(95)96176-E","article-title":"927 a phase I and bioavailability study of oral topotecan","volume":"31","author":"Eckardt","year":"1995","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.jconrel.2026.115166_bb0130","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/bjc.1996.243","article-title":"Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor","volume":"73","author":"Schellens","year":"1996","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.jconrel.2026.115166_bb0135","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/sj.bjc.6690532","article-title":"Oral topotecan: bioavailability and effect of food co-administration","volume":"80","author":"Herben","year":"1999","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.jconrel.2026.115166_bb0140","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2004.07.110","article-title":"Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors","volume":"22","author":"Daw","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115166_bb0145","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1200\/JCO.1999.17.2.685","article-title":"Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors","volume":"17","author":"Drengler","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115166_bb0150","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00280-004-0874-2","article-title":"Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours","volume":"55","author":"Schoemaker","year":"2005","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115166_bb0155","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/annonc\/mdl071","article-title":"A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours","volume":"17","author":"Dumez","year":"2006","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115166_bb0160","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1158\/1078-0432.CCR-04-1758","article-title":"Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors","volume":"11","author":"Soepenberg","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0165","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00280-018-3720-7","article-title":"Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics","volume":"83","author":"K\u00fcmler","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"8_Supplement_2","key":"10.1016\/j.jconrel.2026.115166_bb0170","doi-asserted-by":"crossref","first-page":"LB266","DOI":"10.1158\/1538-7445.AM2025-LB266","article-title":"Abstract LB266: a multicenter phase 1-2a clinical study of Orotecan\u00ae(oral irinotecan HCl, VAL-413) in patients with recurrent pediatric solid tumors","volume":"85","author":"Bacha","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115166_bb0175","series-title":"A First-in-Human Phase I Study of CZ48, a Lactone Ring Protected Oral Camptothecin, in Patients with Advanced Solid Tumors","author":"Mahalingam","year":"2013"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0180","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s002800050789","article-title":"Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071)","volume":"42","author":"Mani","year":"1998","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115166_bb0185","first-page":"1915","article-title":"Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors","volume":"4","author":"Sparreboom","year":"1998","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115166_bb0190","first-page":"4101","article-title":"Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors","volume":"9","author":"Gelderblom","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115166_bb0195","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/0091270004270225","article-title":"Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory cancer patients in a bridging phase I study","volume":"45","author":"Chatterjee","year":"2005","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0200","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1158\/1078-0432.CCR-08-1024","article-title":"Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors","volume":"15","author":"Zhu","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0205","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00001813-199801000-00004","article-title":"A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor","volume":"9","author":"Verschraegen","year":"1998","journal-title":"Anti-Cancer Drugs"},{"issue":"7","key":"10.1016\/j.jconrel.2026.115166_bb0210","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1177\/0091270004265647","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of an orally active novel camptothecin analog, DRF-1042, in refractory cancer patients in a phase I dose escalation study","volume":"44","author":"Chatterjee","year":"2004","journal-title":"J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115166_bb0215","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11060-012-1023-0","article-title":"A phase II trial of oral gimatecan for recurrent glioblastoma","volume":"111","author":"Hu","year":"2013","journal-title":"J. Neuro-Oncol."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115166_bb0220","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/annonc\/mdl418","article-title":"Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors","volume":"18","author":"Sessa","year":"2007","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115166_bb0225","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ejca.2009.11.006","article-title":"Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to \u03b11-acid glycoprotein plasma levels","volume":"46","author":"Frapolli","year":"2010","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115166_bb0230","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/annonc\/mdp514","article-title":"Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes","volume":"21","author":"Pecorelli","year":"2010","journal-title":"Ann. Oncol."},{"issue":"18_suppl","key":"10.1016\/j.jconrel.2026.115166_bb0235","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1200\/jco.2006.24.18_suppl.662","article-title":"A phase II trial of the novel oral camptothecin gimatecan (G) in women with anthracycline (A) and taxane (T) pre-treated advanced breast cancer","volume":"24","author":"Mariani","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"18_suppl","key":"10.1016\/j.jconrel.2026.115166_bb0240","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1200\/jco.2006.24.18_suppl.1559","article-title":"Phase I trial and pharmacokinetic study of oral gimatecan in adults with malignant glioma","volume":"24","author":"Hochberg","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115166_bb0245","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00001813-199904000-00005","article-title":"A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer","volume":"10","author":"Verschraegen","year":"1999","journal-title":"Anti-Cancer Drugs"},{"issue":"5","key":"10.1016\/j.jconrel.2026.115166_bb0250","first-page":"821","article-title":"A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer","volume":"14","author":"Stehlin","year":"1999","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0255","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1749-6632.2000.tb07061.x","article-title":"Phase I study of 9-nitro-20 (S)-camptothecin in combination with cisplatin for patients with advanced malignancies","volume":"922","author":"Verschraegen","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115166_bb0260","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s002800100360","article-title":"A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma","volume":"48","author":"Konstadoulakis","year":"2001","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115166_bb0265","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00001813-200202000-00009","article-title":"Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma","volume":"13","author":"Ellerhorst","year":"2002","journal-title":"Anti-Cancer Drugs"},{"issue":"10","key":"10.1016\/j.jconrel.2026.115166_bb0270","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S0959-8049(02)00070-9","article-title":"Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme","volume":"38","author":"Raymond","year":"2002","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.jconrel.2026.115166_bb0275","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0959-8049(02)00022-9","article-title":"Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer\u2014significant effect of food intake on the bioavailability of the oral camptothecin analogue","volume":"38","author":"Sch\u00f6ffski","year":"2002","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"10.1016\/j.jconrel.2026.115166_bb0280","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/annonc\/mdf342","article-title":"Phase I study of rubitecan and gemcitabine in patients with advanced malignancies","volume":"13","author":"Fracasso","year":"2002","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0285","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/cncr.11038","article-title":"A phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors","volume":"97","author":"Michaelson","year":"2003","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.jconrel.2026.115166_bb0290","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1002\/cncr.11385","article-title":"Results of a 2-arm phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas","volume":"97","author":"Patel","year":"2003","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115166_bb0295","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1023\/B:DRUG.0000026260.24275.02","article-title":"Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors","volume":"22","author":"De Jonge","year":"2004","journal-title":"Investig. New Drugs"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0300","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1023\/B:DRUG.0000006176.84915.71","article-title":"A phase II study of 9-nitro-camptothecin in patients with previously treated metastatic breast cancer","volume":"22","author":"Miller","year":"2004","journal-title":"Investig. New Drugs"},{"issue":"6","key":"10.1016\/j.jconrel.2026.115166_bb0305","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00280-004-0835-9","article-title":"Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors","volume":"54","author":"Jung","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"15","key":"10.1016\/j.jconrel.2026.115166_bb0310","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-03-0288","article-title":"Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors","volume":"10","author":"Zamboni","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.jconrel.2026.115166_bb0315","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.ejca.2004.02.016","article-title":"RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group","volume":"40","author":"Punt","year":"2004","journal-title":"Eur. J. Cancer"},{"issue":"14_suppl","key":"10.1016\/j.jconrel.2026.115166_bb0320","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1200\/jco.2004.22.90140.4013","article-title":"A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study","volume":"22","author":"Jacobs","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.jconrel.2026.115166_bb0325","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1200\/JCO.2005.02.170","article-title":"Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma","volume":"23","author":"Chugh","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0330","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.radonc.2005.04.005","article-title":"A phase I study of concurrent 9-nitro-20 (s)-camptothecin (9NC\/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas","volume":"76","author":"Tedesco","year":"2005","journal-title":"Radiother. Oncol."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115166_bb0335","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.ejca.2005.03.009","article-title":"A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer","volume":"41","author":"Baka","year":"2005","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115166_bb0340","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1634\/theoncologist.10-3-183","article-title":"Phase II trial of oral rubitecan in previously treated pancreatic cancer patients","volume":"10","author":"Burris","year":"2005","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.jconrel.2026.115166_bb0345","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00280-005-0084-6","article-title":"Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors","volume":"57","author":"Zamboni","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115166_bb0350","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10637-006-6451-2","article-title":"Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy","volume":"24","author":"Patel","year":"2006","journal-title":"Investig. New Drugs"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115166_bb0355","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00280-007-0592-7","article-title":"Phase II study of rubitecan in recurrent or metastatic head and neck cancer","volume":"62","author":"Caponigro","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"15","key":"10.1016\/j.jconrel.2026.115166_bb0360","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1200\/JCO.2006.08.3998","article-title":"Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer","volume":"25","author":"Eckardt","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115166_bb0365","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1200\/JCO.2001.19.6.1743","article-title":"Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer","volume":"19","author":"von Pawel","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115166_bb0370","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1200\/JCO.1999.17.7.2219","article-title":"Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors","volume":"17","author":"de Jonge","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115166_bb0375","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0009-9236(99)70068-8","article-title":"Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva","volume":"65","author":"De Jonge","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0380","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1021\/cr0780210","article-title":"Camptothecins: a SAR\/QSAR study","volume":"109","author":"Verma","year":"2009","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2026.115166_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115710","article-title":"The recent developments of camptothecin and its derivatives as potential anti-tumor agents","volume":"260","author":"Wang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"18","key":"10.1016\/j.jconrel.2026.115166_bb0390","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1016\/j.bmcl.2015.07.032","article-title":"Interfacial inhibitors","volume":"25","author":"Pommier","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"24","key":"10.1016\/j.jconrel.2026.115166_bb0395","doi-asserted-by":"crossref","first-page":"15387","DOI":"10.1073\/pnas.242259599","article-title":"The mechanism of topoisomerase I poisoning by a camptothecin analog","volume":"99","author":"Staker","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0400","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1517\/13543780802571674","article-title":"Diflomotecan, a promising homocamptothecin for cancer therapy","volume":"18","author":"Kroep","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"12","key":"10.1016\/j.jconrel.2026.115166_bb0405","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1158\/1535-7163.MCT-07-0441","article-title":"Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters","volume":"6","author":"Takagi","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0410","doi-asserted-by":"crossref","first-page":"115","DOI":"10.18433\/J3B604","article-title":"Enhanced lactone stability of CZ48 in blood correlates to its lack of toxicity in mice","volume":"16","author":"Liu","year":"2013","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"9_Supplement","key":"10.1016\/j.jconrel.2026.115166_bb0415","first-page":"764","article-title":"Activation of the non-toxic prodrug CZ48 in many human and mouse tumor tissues is much higher than in human and mouse normal tissues","volume":"68","author":"Markides","year":"2008","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115166_bb0420","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","article-title":"Sacituzumab govitecan: first approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115166_bb0425","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/med.21342","article-title":"Perspectives on biologically active camptothecin derivatives","volume":"35","author":"Liu","year":"2015","journal-title":"Med. Res. Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115166_bb0430","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1021\/mp900243b","article-title":"Cancer therapies utilizing the camptothecins: a review of the in vivo literature","volume":"7","author":"Venditto","year":"2010","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115166_bb0435","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1021\/acs.jmedchem.8b00686","article-title":"Two decades under the influence of the rule of five and the changing properties of approved oral drugs: miniperspective","volume":"62","author":"Shultz","year":"2018","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115166_bb0440","first-page":"777","article-title":"Re-assessing the rule of 5, two decades on","volume":"17","author":"Mullard","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0445","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jconrel.2013.07.022","article-title":"Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38","volume":"172","author":"Bala","year":"2013","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115166_bb0450","doi-asserted-by":"crossref","DOI":"10.1093\/femsre\/fuad022","article-title":"The small intestine: dining table of host\u2013microbiota meetings","volume":"47","author":"Delbaere","year":"2023","journal-title":"FEMS Microbiol. Rev."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115166_bb0455","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1023\/A:1015827908309","article-title":"Upper gastrointestinal (GI) pH in young, healthy men and women","volume":"7","author":"Dressman","year":"1990","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115166_bb0460","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bcpt.12342","article-title":"Mucus as a barrier to drug delivery\u2013understanding and mimicking the barrier properties","volume":"116","author":"Boegh","year":"2015","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115166_bb0465","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1021\/acs.jcim.3c01629","article-title":"Impact of the unstirred water layer on the permeation of small-molecule drugs","volume":"64","author":"Kang","year":"2024","journal-title":"J. Chem. Inf. Model."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115166_bb0470","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.apsb.2018.05.005","article-title":"Human carboxylesterases: a comprehensive review","volume":"8","author":"Wang","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"issue":"12","key":"10.1016\/j.jconrel.2026.115166_bb0475","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1517\/17425247.2015.1070142","article-title":"Challenges in SN38 drug delivery: current success and future directions","volume":"12","author":"Palakurthi","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.115166_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115032","article-title":"Irinotecan-mediated diarrhea is mainly correlated with intestinal exposure to SN-38: critical role of gut Ugt","volume":"398","author":"Sun","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115166_bb0485","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1124\/dmd.121.000476","article-title":"Quantitative investigation of irinotecan metabolism, transport, and gut microbiome activation","volume":"49","author":"Parvez","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jconrel.2026.115166_bb0500","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bbrc.2023.04.109","article-title":"Transporter and metabolic enzyme-mediated intra-enteric circulation of SN-38, an active metabolite of irinotecan: a new concept","volume":"665","author":"Martha","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0490","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/s41598-018-36069-w","article-title":"Structure, function, and inhibition of drug reactivating human gut microbial \u03b2-glucuronidases","volume":"9","author":"Biernat","year":"2019","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115166_bb0495","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1080\/17425247.2023.2233900","article-title":"Targeting the gut microbiome to control drug pharmacomicrobiomics: the next frontier in oral drug delivery","volume":"20","author":"Kamath","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115166_bb0505","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13060869","article-title":"A biophysical insight of camptothecin biodistribution: towards a molecular understanding of its pharmacokinetic issues","volume":"13","author":"Almeida","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0510","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1208\/s12249-011-9720-0","article-title":"Soluplus-solubilized citrated camptothecin\u2014a potential drug delivery strategy in colon cancer","volume":"13","author":"Thakral","year":"2012","journal-title":"AAPS PharmSciTech"},{"issue":"11","key":"10.1016\/j.jconrel.2026.115166_bb0515","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17111414","article-title":"Camptothecin in cancer therapy: current challenges and emerging strategies with nanoemulsions","volume":"17","author":"P\u00e9rez-Ortega","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115166_bb0520","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jconrel.2021.05.017","article-title":"Oral delivery of topotecan in polymeric nanoparticles: lymphatic distribution and pharmacokinetics","volume":"335","author":"Jeong","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115166_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116872","article-title":"Drug combinations of camptothecin derivatives promote the antitumor properties","volume":"279","author":"Liu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115166_bb0530","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17101289","article-title":"Enteric coating enhances the biopharmaceutical performance of a silica\u2013lipid formulation of abiraterone acetate","volume":"17","author":"Taheri","year":"2025","journal-title":"Pharmaceutics"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2026.115166_bb0535","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0378-5173(03)00287-4","article-title":"Enzyme-mediated precipitation of parent drugs from their phosphate prodrugs","volume":"261","author":"Heimbach","year":"2003","journal-title":"Int. J. Pharm."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115166_bb0540","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.addr.2007.05.013","article-title":"Prodrug strategies to overcome poor water solubility","volume":"59","author":"Stella","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115166_bb0545","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1007\/s13346-024-01755-y","article-title":"Enhancing the pharmacokinetics of abiraterone acetate through lipid-based formulations: addressing solubility and food effect challenges","volume":"15","author":"Taheri","year":"2025","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2026.115166_bb0550","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejpb.2016.05.021","article-title":"Facilitating gastrointestinal solubilisation and enhanced oral absorption of SN38 using a molecularly complexed silica-lipid hybrid delivery system","volume":"105","author":"Bala","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115166_bb0555","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/(SICI)1097-0215(19991112)83:4<491::AID-IJC10>3.0.CO;2-M","article-title":"pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells","volume":"83","author":"Kobayashi","year":"1999","journal-title":"Int. J. Cancer"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2026.115166_bb0560","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijpharm.2003.12.023","article-title":"Transport characteristics of 9-nitrocamptothecin in the human intestinal cell line Caco-2 and everted gut sacs","volume":"272","author":"Sha","year":"2004","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115166_bb0565","article-title":"Design principles for balancing lipophilicity and permeability in beyond rule of 5 space","volume":"19","author":"M\u00f6bitz","year":"2024","journal-title":"ChemMedChem"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0570","doi-asserted-by":"crossref","first-page":"1700297","DOI":"10.1002\/ardp.201700297","article-title":"Silicon-containing analogs of camptothecin as anticancer agents","volume":"351","author":"Lazareva","year":"2018","journal-title":"Arch. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0575","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1021\/acs.molpharmaceut.5b00785","article-title":"Lipophilic prodrugs of SN38: synthesis and in vitro characterization toward oral chemotherapy","volume":"13","author":"Bala","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115166_bb0580","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ejmech.2014.06.050","article-title":"A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability","volume":"83","author":"Rodr\u00edguez-Berna","year":"2014","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0585","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.addr.2011.12.008","article-title":"Improving the prediction of the brain disposition for orally administered drugs using BDDCS","volume":"64","author":"Broccatelli","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"8_Supplement","key":"10.1016\/j.jconrel.2026.115166_bb0590","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1158\/1538-7445.AM10-3547","article-title":"The differences in intestinal absorptions between CZ48 and its parental Camptothecin","volume":"70","author":"Liu","year":"2010","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115166_bb0595","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1124\/dmd.119.088674","article-title":"The impact of breast cancer resistance protein (BCRP\/ABCG2) on drug transport across Caco-2 cell monolayers","volume":"48","author":"Kawahara","year":"2020","journal-title":"Drug Metab. Dispos."},{"issue":"22","key":"10.1016\/j.jconrel.2026.115166_bb0600","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28227532","article-title":"Study models of drug\u2013drug interactions involving P-glycoprotein: the potential benefit of P-glycoprotein modulation at the kidney and intestinal levels","volume":"28","author":"Veiga-Matos","year":"2023","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.jconrel.2026.115166_bb0605","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1158\/0008-5472.CAN-03-3344","article-title":"Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro","volume":"64","author":"Houghton","year":"2004","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115166_bb0610","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1007\/s11095-008-9678-0","article-title":"Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells","volume":"25","author":"Li","year":"2008","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115166_bb0615","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.taap.2013.12.018","article-title":"Optimization of irinotecan chronotherapy with P-glycoprotein inhibition","volume":"274","author":"Filipski","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115166_bb0620","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/jpp\/rgaa009","article-title":"Possible roles of intestinal P-glycoprotein and cytochrome P450 3A on the limited oral absorption of irinotecan","volume":"73","author":"Yamasaki","year":"2021","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.115166_bb0625","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.toxlet.2024.02.011","article-title":"Roles of breast cancer resistance protein and organic anion transporting polypeptide 2B1 in gastrointestinal toxicity induced by SN-38 under inflammatory conditions","volume":"394","author":"Gulnaz","year":"2024","journal-title":"Toxicol. Lett."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0630","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/dmd.115.066712","article-title":"Organic anion transporting polypeptide (OATP) 2B1 contributes to gastrointestinal toxicity of anticancer drug SN-38, active metabolite of irinotecan hydrochloride","volume":"44","author":"Fujita","year":"2016","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0635","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12943-015-0362-9","article-title":"FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance","volume":"14","author":"Westover","year":"2015","journal-title":"Mol. Cancer"},{"issue":"10","key":"10.1016\/j.jconrel.2026.115166_bb0640","first-page":"1765","article-title":"FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models","volume":"7","author":"Ling","year":"2015","journal-title":"Am. J. Transl. Res."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115166_bb0645","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/1097-0215(20001015)88:2<260::AID-IJC18>3.0.CO;2-Q","article-title":"New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer","volume":"88","author":"Van Hattum","year":"2000","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.jconrel.2026.115166_bb0650","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.645","article-title":"Inter-individual and inter-regional variations in enteric drug metabolizing enzyme activities: results with cryopreserved human intestinal mucosal epithelia (CHIM) from the small intestines of 14 donors","volume":"8","author":"Li","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0655","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1517\/13543784.15.1.71","article-title":"Rubitecan","volume":"15","author":"Clark","year":"2006","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0660","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/0929867033368619","article-title":"Lessons learned from the irinotecan metabolic pathway","volume":"10","author":"Ma","year":"2003","journal-title":"Curr. Med. Chem."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115166_bb0665","first-page":"3228","article-title":"Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin","volume":"63","author":"Rajendra","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115166_bb0670","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jconrel.2023.10.002","article-title":"Battle of the milky way: lymphatic targeted drug delivery for pathogen eradication","volume":"363","author":"Taheri","year":"2023","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.jconrel.2026.115166_bb0675","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1124\/pharmrev.123.001159","article-title":"Intestinal lymphatic biology, drug delivery, and therapeutics: current status and future directions","volume":"76","author":"Reddiar","year":"2024","journal-title":"Pharmacol. Rev."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115166_bb0680","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nrd4608","article-title":"From sewer to saviour\u2014targeting the lymphatic system to promote drug exposure and activity","volume":"14","author":"Trevaskis","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115166_bb0685","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3390\/cells10030627","article-title":"Progression of metastasis through lymphatic system","volume":"10","author":"Zhou","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100746","article-title":"The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan","volume":"8","author":"Su","year":"2023","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.jconrel.2026.115166_bb0695","first-page":"2012","article-title":"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans","volume":"6","author":"Santos","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115166_bb0700","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/bcp.12606","article-title":"Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function","volume":"80","author":"Devriese","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115166_bb0705","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/00001813-199808000-00002","article-title":"O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan","volume":"9","author":"Rosing","year":"1998","journal-title":"Anti-Cancer Drugs"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0710","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00280-002-0454-2","article-title":"Urinary and fecal excretion of topotecan in patients with malignant solid tumours","volume":"50","author":"Herben","year":"2002","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0715","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s43094-026-00940-9","article-title":"Belotecan in ovarian cancer anti-inflammatory potential and mechanistic insight to nano-formulations","volume":"12","author":"Kumar","year":"2026","journal-title":"Future J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115166_bb0720","series-title":"Camptothecins in cancer Therapy","first-page":"317","article-title":"Preclinical and clinical development of Exatecan (DX-951f) a hexacyclic camptothecin analog","author":"Rowinsky","year":"2005"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0725","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clpt.2004.03.003","article-title":"Diflomotecan pharmacokinetics in relation to ABCG2 421C> A genotype","volume":"76","author":"Sparreboom","year":"2004","journal-title":"Clin. Pharmacol. Ther. (St. Louis, MO, U. S.)"},{"key":"10.1016\/j.jconrel.2026.115166_bb0730","first-page":"1","article-title":"The expanding role of formulations to enable oral delivery of poorly water-soluble drugs","author":"Ueda","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0735","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejpb.2011.01.021","article-title":"Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration","volume":"79","author":"Roger","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115166_bb0740","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1124\/dmd.106.014217","article-title":"Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients","volume":"35","author":"Yamagata","year":"2007","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115166_bb0745","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.xphs.2018.10.043","article-title":"Modulation of intestinal transport and absorption of topotecan, a BCRP substrate, by various pharmaceutical excipients and their inhibitory mechanisms of BCRP transporter","volume":"108","author":"Sawangrat","year":"2019","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115166_bb0750","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13040559","article-title":"Dual inhibition of P-gp and BCRP improves oral topotecan bioavailability in rodents","volume":"13","author":"Lee","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115166_bb0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2023.113736","article-title":"Enhancing oral delivery and anticancer efficacy of 7-ethyl-10-hydroxycamptothecin through self-assembled micelles of deoxycholic acid grafted N'-nonyl-trimethyl chitosan","volume":"234","author":"Huang","year":"2024","journal-title":"Colloids Surf. B: Biointerfaces"},{"issue":"7","key":"10.1016\/j.jconrel.2026.115166_bb0760","first-page":"2685","article-title":"Inter-and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens","volume":"6","author":"Loos","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115166_bb0765","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jconrel.2022.07.029","article-title":"Oral delivery of camptothecin-loaded multifunctional chitosan-based micelles is effective in reduce colorectal cancer","volume":"349","author":"Almeida","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115166_bb0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119468","article-title":"Cyclodextrin nanoparticle bound oral camptothecin for colorectal cancer: formulation development and optimization","volume":"584","author":"\u00dcnal","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115166_bb0775","article-title":"Nanoparticles from Gantrez-based conjugates for the oral delivery of camptothecin","volume":"3","author":"Huarte","year":"2021","journal-title":"Int. J. Pharm. X"},{"key":"10.1016\/j.jconrel.2026.115166_bb0780","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.2147\/IJN.S193783","article-title":"One-step mechanochemical preparation and prominent antitumor activity of SN-38 self-micelle solid dispersion","author":"Sun","year":"2019","journal-title":"Int. J. Nanomedicine"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115166_bb0785","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jconrel.2010.11.022","article-title":"G3. 5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity","volume":"150","author":"Goldberg","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115166_bb0790","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ijbiomac.2022.05.060","article-title":"Orally delivered solid lipid nanoparticles of irinotecan coupled with chitosan surface modification to treat colon cancer: preparation, in-vitro and in-vivo evaluations","volume":"211","author":"Bhaskaran","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2026.115166_bb0795","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.colsurfb.2013.06.001","article-title":"Nano scale self-emulsifying oil based carrier system for improved oral bioavailability of camptothecin derivative by P-glycoprotein modulation","volume":"111","author":"Negi","year":"2013","journal-title":"Colloids Surf. B: Biointerfaces"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115166_bb0800","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.ejpb.2008.02.023","article-title":"Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice","volume":"69","author":"Lu","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2026.115166_bb0805","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ijpharm.2014.10.055","article-title":"Soluplus\u00ae based 9-nitrocamptothecin solid dispersion for peroral administration: preparation, characterization, in vitro and in vivo evaluation","volume":"477","author":"Lian","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115166_bb0810","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2022.103850","article-title":"Qbd based and box-Behnken design assisted Oral delivery of stable lactone (active) form of Topotecan as PLGA nanoformulation: cytotoxicity, pharmacokinetic, in vitro, and ex vivo gut permeation studies","volume":"77","author":"Khuroo","year":"2022","journal-title":"J. Drug Delivery Sci. Technol."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115166_bb0815","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41573-024-00914-7","article-title":"The landscape of small-molecule prodrugs","volume":"23","author":"Fralish","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115166_bb0820","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1021\/acs.molpharmaceut.6b00591","article-title":"Enabling oral SN38-based chemotherapy with a combined lipophilic prodrug and self-microemulsifying drug delivery system","volume":"13","author":"Bala","year":"2016","journal-title":"Mol. Pharm."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115166_bb0835","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1021\/jm401644v","article-title":"Macromolecular prodrug that provides the irinotecan (CPT-11) active-metabolite SN-38 with ultralong half-life, low C max, and low glucuronide formation","volume":"57","author":"Santi","year":"2014","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0840","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/s42003-022-04191-1","article-title":"Anti-tumor effects of P-LPK-CPT, a peptide-camptothecin conjugate, in colorectal cancer","volume":"5","author":"Hou","year":"2022","journal-title":"Commun. Biol."},{"issue":"45","key":"10.1016\/j.jconrel.2026.115166_bb0845","doi-asserted-by":"crossref","first-page":"50248","DOI":"10.1021\/acsami.0c13943","article-title":"Injectable reactive oxygen species-responsive SN38 prodrug scaffold with checkpoint inhibitors for combined chemoimmunotherapy","volume":"12","author":"Gong","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2026.115166_bb0850","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jconrel.2024.04.019","article-title":"Enhancing SN38 prodrug delivery using a self-immolative linker and endogenous albumin transport","volume":"369","author":"Jiang","year":"2024","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0825","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1208\/s12248-014-9670-z","article-title":"Lipid-based drug carriers for prodrugs to enhance drug delivery","volume":"17","author":"Zaro","year":"2015","journal-title":"AAPS J."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115166_bb0830","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/med.21533","article-title":"Lipidic prodrug approach for improved oral drug delivery and therapy","volume":"39","author":"Markovic","year":"2019","journal-title":"Med. Res. Rev."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115166_bb0855","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1021\/acs.molpharmaceut.4c00202","article-title":"Physiologically based biopharmaceutics modeling (PBBM): best practices for drug product quality, regulatory and industry perspectives: 2023 workshop summary report","volume":"21","author":"Mackie","year":"2024","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115166_bb0860","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1124\/dmd.123.001487","article-title":"Physiologically-based pharmacokinetic modeling for drugs cleared by non-cytochrome p450 enzymes: state-of-the-art and future perspectives","volume":"52","author":"Ozbey","year":"2024","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115166_bb0865","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2125.2010.03695.x","article-title":"Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients","volume":"70","author":"Sai","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115166_bb0870","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1124\/dmd.105.005587","article-title":"Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2)","volume":"33","author":"Kubo","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jconrel.2026.115166_bb0875","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/PGPM.S108656","article-title":"UGT1A1 polymorphisms in cancer: impact on irinotecan treatment","author":"Takano","year":"2017","journal-title":"Pharmacogenomics Personalized Med."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115166_bb0880","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.tox.2010.06.007","article-title":"PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals","volume":"278","author":"Bois","year":"2010","journal-title":"Toxicology"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926005699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926005699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:18:32Z","timestamp":1787804312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926005699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":176,"alternative-id":["S0168365926005699"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115166","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral delivery of topoisomerase I inhibitors: From biopharmaceutical barriers to clinical translation","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115166","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115166"}}